Acutaas Chemicals Quarterly Results for Trading Insights
In Mar 2026, Acutaas Chemicals (ACUTAAS) reported revenue ₹444 Cr and net profit ₹134 Cr — revenue +41.4% YoY. View Acutaas Chemicals yearly highs lows for the annual high/low range and current price position.
ACUTAAS Quarterly Results — Revenue, Profit & EPS Highlights
Acutaas Chemicals latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Analyse Acutaas Chemicals ownership pattern to track promoter, FII and institutional holdings.
- Revenue of ₹444 Cr in Mar 2026 (+33.7% vs Jun 2026, +41.4% vs Mar 2025)
- Net Profit of ₹134 Cr in Mar 2026 (+78.7% vs Jun 2026, +112.7% vs Mar 2025)
- EBITDA of ₹195 Cr in Mar 2026 (+69.6% vs Jun 2026)
- Operating Margin of 42.0% in Mar 2026 (+8.0pp vs Jun 2026)
- Earnings Per Share of ₹16.09 in Mar 2026 (+77.4% vs Jun 2026)
Acutaas Chemicals Quarterly Results — Revenue, EBITDA, Net Profit & EPS
ACUTAAS quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Jun 2026 | Sept 2025 | Mar 2025 | Jun 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 444 | 332 | 316 | 314 | 223 | 33.7% | 41.4% |
| Net Profit (₹ Cr) | 134 | 75 | 72 | 63 | 44 | - | - |
| EBITDA (₹ Cr) | 195 | 115 | 105 | 91 | 67 | - | - |
| EPS (₹) | 16.09 | 9.07 | 8.82 | 7.80 | 5.41 | - | - |
| Operating Margin (%) | 42.0% | 34.0% | 31.0% | 28.0% | 25.0% | - | - |
ACUTAAS Share Price Trend — 1-Year Movement Across Quarterly Results
Acutaas Chemicals 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. For annual financials, live price and key ratios, visit Acutaas Chemicals share price chart.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
ACUTAAS vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Acutaas Chemicals latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹441,477.63 Cr | 1837.3 | 15,018 | 2,710 | -5.6% | - | 18.0% | 162.6 |
|
Divis Laboratories
Mar 2026 |
₹247,469.81 Cr | 9375.0 | 2,986 | 751 | -5.0% | - | 25.2% | 331.2 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4840.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 420.5 |
|
Cipla
Mar 2026 |
₹112,654.03 Cr | 1394.5 | 6,612 | 543 | -9.3% | - | 8.2% | 203.0 |
|
Zydus Life Science
Mar 2026 |
₹112,607.65 Cr | 1160.0 | 7,569 | 1,341 | -4.3% | - | 17.7% | 91.7 |
All amounts in ₹ Crores